Gene therapy infused directly into brain aims to halt rare dementia
Disease control
Recruiting now
This early-phase trial tests a gene therapy called AVB-101 for people with frontotemporal dementia caused by GRN gene mutations. The therapy delivers a working copy of the GRN gene directly into the brain during a one-time procedure. The study will enroll 18 adults aged 30-75 to …
Phase: PHASE1, PHASE2 • Sponsor: AviadoBio Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC